Urea

Urea

SCHEMBL2156950

Cc1cccc(C)c1NC(=O)Nc1ccc([N+](=O)[O-])cc1.NC(N)=O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.64
MEN1 O00255 8/20 0.64
ALDH1A1 P00352 3/20 0.60
NPC1 O15118 6/20 0.59
RAB9A P51151 4/20 0.59
MAPT P10636 7/20 0.57
MAPK1 P28482 3/20 0.57
LMNA P02545 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
NPSR1 Q6W5P4 2/20 0.55
MYOC Q99972 2/20 0.55
DDX3X O00571 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
HTT P42858 1/20 0.51
RORC P51449 1/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4954984 0.96 KMT2A (0.70) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL8103094 0.88 KMT2A (0.74) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL6939617 0.88 KMT2A (0.60) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL17978616 0.80 DDX3X (0.73) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL1177730 0.80 MEN1 (1.00) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6302157 0.80 MEN1 (1.00) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL4115432 0.79 MEN1 (0.82) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6501234 0.77 MEN1 (0.59) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL11055960 0.77 MEN1 (0.85) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL4347168 0.77 KMT2A (0.61) KMT2AMEN1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973034-B2 Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2011-07-05 US disclosed
US-20080146548-A1 AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2008-06-19 US disclosed
US-20050054691-A1 Carboxylesterase inhibitors ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054691-A1 Carboxylesterase inhibitors CES1, CES2, BCHE KMT2A 1241/4885MEN1 4615/4885ALDH1A1 227/4885
US-20080146548-A1 AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE CES1, BCHE, CES2 KMT2A 943/4885MEN1 4755/4885ALDH1A1 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.